We are live on ! Find out more
NTLA icon

Intellia Therapeutics
NTLA

290 hedge funds and large institutions have $2.93B invested in Intellia Therapeutics in 2023 Q1 according to their latest regulatory filings, with 34 funds opening new positions, 107 increasing their positions, 91 reducing their positions, and 47 closing their positions.

New
Increased
Maintained
Reduced
Closed

51% more call options, than puts

Call options by funds: $18.7M | Put options by funds: $12.4M

18% more repeat investments, than reductions

Existing positions increased: 107 | Existing positions reduced: 91

9% more capital invested

Capital invested by funds: $2.69B → $2.93B (+$235M)

0% more funds holding in top 10

Funds holding in top 10: 7 → 7 (0)

2.1% less ownership

Funds ownership: 91.54% → 89.45% (-2.1%)

4% less funds holding

Funds holding: 303 → 290 (-13)

28% less first-time investments, than exits

New positions opened: 34 | Existing positions closed: 47

Holders
290
Holders Change
-13
Holders Change %
-4.29%
% of All Funds
4.62%
Holding in Top 10
7
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.11%
New
34
Increased
107
Reduced
91
Closed
47
Calls
$18.7M
Puts
$12.4M
Net Calls
+$6.32M
Net Calls Change
-$4.81M

Top Buyers

Rank Fund Capital Flow
1
CC
Casdin Capital
New York
+$38.4M
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$38.1M
3
Bank of America
Bank of America
North Carolina
+$25.6M
4
RCMU
Rokos Capital Management (UK)
United Kingdom
+$22.1M
5
AIM
ARK Investment Management
Florida
+$16.3M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$47.7M
2
T. Rowe Price Investment Management
T. Rowe Price Investment Management
Maryland
-$18.6M
3
Viking Global Investors
Viking Global Investors
Connecticut
-$17.7M
4
WP
Woodline Partners
California
-$17.4M
5
Ameriprise
Ameriprise
Minnesota
-$15.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
IA
326
IFP Advisors
Florida
– -$6K -228 Closed
MCC
327
Money Concepts Capital
Florida
– -$6.98K -200 Closed
RBC
328
Romano Brothers & Co
Illinois
– -$5.79K -166 Closed
LS
329
Leelyn Smith
Illinois
– -$5.34K -153 Closed
FGAM
330
Financial Gravity Asset Management
Texas
– -$19 -35 Closed
AWM
331
Accurate Wealth Management
Florida
– -$756 -20 Closed
ECM
332
Estabrook Capital Management
New York
– -$488 -14 Closed
CS
333
Comerica Securities
Michigan
– -$454 -13 Closed
YC
334
Yarbrough Capital
Tennessee
– -$349 -10 Closed
AF
335
Affiance Financial
Minnesota
– -$209 -6 Closed
CWP
336
Concord Wealth Partners
Virginia
– -$105 -3 Closed
10 11 12 13
14

NTLA Hedge Fund Activity: Q1 2023 in Review

290 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Intellia Therapeutics (NTLA) for Q1 2023, worth a combined $2.93B — up 8.7% from $2.69B a quarter earlier.

Sellers outnumbered buyers: 47 funds closed out of NTLA and 34 opened new positions — a net loss of 13 holders — while 91 trimmed existing stakes and 107 added.

The largest buyer was Casdin Capital, adding an estimated $38.4M. The largest seller was Fidelity Investments, cutting an estimated $47.7M.

  • 290 institutional investors held Intellia Therapeutics (NTLA) as of Q1 2023, down from 303 in Q4 2022.
  • Funds reported $2.93B of Intellia Therapeutics stock for Q1 2023, up 8.7% quarter-over-quarter.
  • 34 funds opened new Intellia Therapeutics positions in Q1 2023 and 47 closed out, a net change of -13 holders.
  • The largest Intellia Therapeutics buyer in Q1 2023 was Casdin Capital, an estimated $38.4M added.
  • The largest Intellia Therapeutics seller in Q1 2023 was Fidelity Investments, an estimated $47.7M sold.

Based on aggregated 13F filings for Q1 2023.